



27 September 2006

The Manager  
Company Announcements  
Australian Stock Exchange  
4th Floor, 20 Bridge Street  
SYDNEY NSW 2000

Dear Sir/Madam,

**RHT: Resonance Health (RHT) Announces Appointment of Edward D. Dooling, Jr  
as President and CEO**

Resonance Health is pleased to announce that it has retained Edward D. Dooling Jr. as the new President and Chief Executive Officer.

“When we began our search for a CEO, we sought a candidate with a unique mix of qualifications. We looked for a senior manager who could drive sales of FerriScan<sup>®</sup> and other potential diagnostic tests in the United States, but also had sales and management experience that would apply to future acquisitions of pathology labs,” explained Resonance Chairman Dr. Gary W. Pace. “Mr. Dooling fills that profile. He possesses a rich history of driving sales, consolidating operations and introducing unique and innovative diagnostic tests. He also managed anatomical pathology operations for one of the largest public pathology companies in the United States. Resonance is fortunate to obtain his services”

Mr. Dooling has extensive senior management experience in several of the most respected anatomic and esoteric testing laboratories in the United States. Mr. Dooling was V.P. and General Manager for Ameripath’s anatomic pathology division and he spent 10 years at DIANON Systems in numerous management positions. Prior to joining DIANON, Mr. Dooling was recognized as the top Junior Officer on the U.S.S. Iowa. He completed his formal education at Villanova University with a Bachelor in Science.

“I think there is great upside potential at Resonance,” commented Mr. Dooling. “I am enthusiastic about the current technologies, as well as the prospects in the pathology market. I look forward to serving the shareholders as the company grows.”

Yours faithfully



Eva Liu  
Company Secretary

Resonance Health Limited ABN: 96 006 762 492